Of note, although immunotherapy is often utilized as a salvage option after disease progression to MAPKi in BRAF-mutated melanoma patients, important studies suggest that acquired resistance to MAPK-targeted therapy 6 is a negative factor for subsequent response to immunotherapy 7-10. Here, BRAF is linked to melanoma.